Provident Data Centers Joins Texas Nuclear Alliance as Founding Member
Austin, TX May 15, 2025 --( PR.com )-- The Texas Nuclear Alliance (TNA) proudly welcomes Provident Data Centers, a private real estate and investment firm managing over 50 data facilities and +6 GW of planned and committed capacity nationwide, as a Founding Member at the Corporate Board Level.
'Provident is leading the way in developing the data centers our always-advancing society need, and nuclear energy offers a reliable, safe, carbon-free power source to meet the industry's energy demands,' said TNA President Reed Clay. 'We can expect the data center and nuclear energy industries to continue working together as our state, nation and world demands more of both.'
'Provident Data Centers was founded in Texas, built in Texas, and is proud to help power Texas into its next chapter. As the first and currently only data center developer to join the Texas Nuclear Alliance's governing board, we fully support Governor Abbott's vision for Texas to lead the nation in AI and energy reliability. We believe safe, firm, carbon-free nuclear energy is foundational to achieving these goals,' said Jack Backes, Principal Strategist for Provident Data Centers.
'We're hopeful the Texas Senate will pass House Bill 14 to establish a state nuclear office and unlock vital funding for the first wave of nuclear construction and supply chain development in decades. Visionary leadership backed by intelligent, long-term investment is exactly what this moment demands. With 40 years of development experience in Texas, Provident is investing in next-generation energy ecosystems —including organizations like the Texas Nuclear Alliance — that strengthen grid stability, support statewide data center infrastructure, and help power Texas' industrial growth,' Backes continued.
About Provident Data Centers
Provident Data Centers, headquartered in Dallas, TX is a community-driven data center developer dedicated to building 'win-win' partnerships with clients and communities. As a division of Provident, a privately held leading real estate and investment firm, Provident Data Centers brings over three decades of real estate development experience to create cutting-edge data centers for enterprise, hyperscale, and telecom clients. This expertise currently spans six states, with over 50 buildings delivering more than +6 GW of planned and committed power. Provident Data Centers streamlines the development process by managing site selection, land acquisition, design and construction, and infrastructure build-out. This comprehensive approach ensures smooth project execution, minimizes risks, and delivers positive outcomes for all stakeholders. With vast industry knowledge, Provident Data Centers brings a transparent approach and continues to focus on innovative, efficient, and scalable solutions for an evolving digital landscape. To learn more, visit www.providentdatacenters.net and follow on LinkedIn.
About the Texas Nuclear Alliance
TNA is the only industry association in Texas dedicated to the advancement of nuclear technology in the state. TNA was formed with a singular mission: to make Texas the Nuclear Capital of the World. Formed in 2022 in the aftermath of Winter Storm Uri, TNA is based on the fundamental premise that if Texas and the world want low-carbon, reliable energy, it can no longer turn its back on nuclear energy. Nuclear is clean, safe, reliable, and secure.
Contact Information:
Texas Nuclear Alliance
Lauren Clay
512-567-7604
Contact via Email
www.texasnuclearalliance.org
Read the full story here: Provident Data Centers Joins Texas Nuclear Alliance as Founding Member
Press Release Distributed by PR.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
ASEAN Point of Care (POC) Diagnostics Market Report 2025-2030
Vietnam emerges as the fastest-growing market, bolstered by strong primary healthcare enhancements. The infectious disease testing segment is set to witness the highest growth, driven by advanced molecular and immunoassay technologies. ASEAN Point of Care Diagnostics Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030" has been added to offering. The ASEAN point of care diagnostics market is projected to expand from USD 1.08 billion in 2025 to USD 1.36 billion by 2030, recording a CAGR of 4.7% over the forecast period. This growth is predominantly driven by favorable government policies and increased funding investments that bolster the demand for Point of Care (POC) testing across the ASEAN region. Governments in ASEAN countries are increasingly adopting POC technologies to enhance health access, reduce costs, and improve patient outcomes. Initiatives including strategic partnerships, research, and nationwide screening campaigns further promote POC usage, offering significant growth opportunities for diagnostic firms. In numerous developing regions where health infrastructure remains underdeveloped, POC devices facilitate the decentralization of diagnostics, thereby broadening access to essential testing. This report categorizes the market by product, technology, end user, and country. It comprehensively covers key growth drivers, restraints, opportunities, and challenges, providing insights into industry players, strategies, and recent developments. A competitive analysis of emerging ASEAN point-of-care diagnostics startups is also included. Key market players include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Sysmex Corporation, and Danaher Corporation, among others. The report provides insights into the following points: Analysis of factors influencing market growth including the rise of infectious and chronic diseases, government initiatives, and public-private partnerships. Product Development/Innovation: Detailed insights into upcoming technologies and new product launches in the ASEAN market. Market Development: Comprehensive information on lucrative markets across ASEAN countries. Market Diversification: Insights into new products, untapped geographies, and investments. Competitive Assessment: In-depth analysis of leading players' market shares, strategies, and offerings. Infectious disease testing products anticipated to register the highest growth rate This market segment encompasses infectious disease testing products, glucose monitoring products, cardiometabolic testing products, among others. The infectious disease testing products segment's rapid growth is driven by ASEAN efforts to enhance disease surveillance. The frequency of infectious disease outbreaks and the need for rapid diagnosis, particularly in rural and urban healthcare settings, underpin this demand. Advances in molecular platforms and immunoassays further foster the sector's expansion. By technology, the Biochemistry segment accounted for the largest market share in 2024 The market is segmented into lateral flow assays, rapid tests, and biochemistry. Biochemistry held the largest share, attributed to its broad applicability in various essential tests such as glucose and electrolyte analysis. The high incidence of chronic diseases in ASEAN countries necessitates these diagnostics, with biochemistry testing's ease of use and cost-effectiveness making it ideal for decentralized healthcare environments. The demand for early disease detection further supports biochemistry's leading position in the market. Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region Within ASEAN, Vietnam is poised for the highest growth, largely due to its initiatives post-COVID-19 to strengthen primary healthcare and nationwide screening. Vietnam's commitment to enhancing healthcare infrastructure, particularly in infectious disease management, is evident in its robust surveillance systems. Their performance in global health security indicators emphasizes their capability to adopt POC diagnostics effectively. Key Attributes Report Attribute Details No. of Pages 334 Forecast Period 2025-2030 Estimated Market Value (USD) in 2025 $1.08 Billion Forecasted Market Value (USD) by 2030 $1.36 Billion Compound Annual Growth Rate 4.7% Regions Covered Asia-Pacific Key Topics CoveredMarket Dynamics Drivers Rising Incidence of Infectious Diseases Increasing Prevalence of Chronic Diseases Favorable Government Initiatives for POC Testing Rising Number of Public-Private Partnerships (PPPs) Challenges Pricing Pressure on Manufacturers Stringent Regulatory Approval Process for Product Commercialization Opportunities Gradual Shift Toward Decentralized Healthcare Systems Availability of POC Tests with Multiplexing Capabilities Industry Trends Trends/Disruptions Impacting Customers' Businesses Companies Profiled in the ASEAN POC Market Abbott F. Hoffmann-La Roche Ltd. Siemens Healthineers AG Sysmex Corporation Danaher Corporation BD Quidelortho Corporation Cardinal Health bioMerieux EKF Diagnostics Holdings PLC Thermo Fisher Scientific Inc. Accubiotech, Co. Ltd. Biosynex SA SD Biosensor, Inc. Sekisui Diagnostics Werfen Trinity Biotech PTS Diagnostics Lifescan IP Holdings, LLC CTK Biotech, Inc. Wondfo Arkray, Inc. Xiamen Boson Biotech Co. Ltd. Credo Diagnostics Biomedical Pte. Ltd. Anbio Biotechnology Inc. SG Diagnostics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment ASEAN Point of Care Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Texas Cyber Command signed into law: What this means for Texans
AUSTIN (KXAN) — On Monday, Texas Gov. Greg Abbott signed House Bill 150, which creates a state-based cybersecurity department, into law. The Texas Cyber Command was passed during the 89th regular legislative session and is expected to help protect Texans against cyber threats. RELATED | Lawmakers file bills to create Texas Cyber Command 'Our state is under constant attack by cyber criminals, attacks that occur thousands of times every single second of every single day,' Abbott said. 'I'm signing a law that creates the Texas Cyber Command. Its ultimate mission is to prevent and protect against cyber breaches. Working together with the Texas Cyber Command, Texas will be on the path to be a national leader in cybersecurity.' According to the governor's office, the Texas Cyber Command will: Launch a cyber threat intelligence center to identify and repair weaknesses and to educate users on preventing cyber breaches Coordinate with governments on responses to cyberattacks Collaborate with local, state and federal partners to establish 'the gold standard for cybersecurity' RELATED | Is your data safe? Lawmakers say it's time for a Texas Cyber Command The department, which is headquartered in San Antonio, was funded through a $135 million investment, according to the governor's office. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
a day ago
- Yahoo
Kalorama Forecasts $2.3 Billion HbA1c Market by 2029, Driven by POC Growth, Emerging Markets, and Digital Innovation
ARLINGTON, Va., June 4, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of healthcare market research, has released The World Market for HbA1c Testing: Trends, Technologies, and Growth Opportunities, 2025, in conjunction with a related webinar held in April. This comprehensive report delivers critical insights for diagnostic developers, healthcare providers, investors, and strategic planners navigating the rapidly expanding global HbA1c testing market. In 2024, the global HbA1c in vitro diagnostics (IVD) market generated $1.7 billion and is projected to reach $2.3 billion by 2029, reflecting a compound annual growth rate (CAGR) of 5.7%. The report underscores the growing role of HbA1c testing in diabetes screening, monitoring, and personalized care—particularly as point-of-care (POC) adoption accelerates to meet demand for fast, decentralized diagnostics. "Laboratory-based testing has long been the gold standard for HbA1c," said Daniel Granderson, Senior Editor at Kalorama Information. "But with advancing technology and rising demand, we're seeing a significant shift toward POC testing. These platforms have been a major driver of diagnostics market growth over the past decade." Key Findings: North America and Europe accounted for over 73% of 2024 revenues, but Asia-Pacific and Latin America are gaining momentum due to aging populations, rising diabetes prevalence, and expanding healthcare systems. Lab-based HbA1c testing remains dominant, but POC platforms are growing faster due to convenience and innovation. Abbott leads the market with a 17% share, followed by Roche (11%) and Bio-Rad. The top five HbA1c competitors combine to account for 45% of the overall market. Emerging technologies—nanotech, mobile-connected assays, AI, and deep learning—are enabling real-time, home-based monitoring and predictive care. Why This Report Matters Now: As global diabetes rates climb and healthcare systems emphasize chronic disease management and cost control, HbA1c testing is central to improving outcomes. The integration of digital tools, biosensor innovation, and government screening programs is reshaping how and where testing is done. This report gives stakeholders a clear view of: Where growth is happening (geographically and technologically) How to enter or expand in the market Which products and competitors are gaining share What barriers exist in reimbursement, pricing, and procurement How to prioritize investments and R&D pipelines Who Should Read This Report: Diagnostic & Medical Device Companies Strategic Planners & Business Development Leaders Investors and Venture Capital Firms Healthcare Providers and Laboratory Networks Policy Makers and Reimbursement Authorities Whether you're building a product roadmap, evaluating acquisition targets, or justifying a strategic pivot, this report provides the data, competitive intelligence, and trend forecasting you need to move forward with confidence. Access the Report & Webinar Purchase the Report Watch the Webinar Replay For more information or to request a custom consultation, contact:Sheri DavieKalorama Information Sales For all other inquiries contact:Alisa AlvichMarketing About Kalorama Information For over 20 years, Kalorama Information has been a trusted source of healthcare market research, specializing exclusively in areas such as in vitro diagnostics (IVD), medical devices, sequencing, cell and gene therapy, and pharmaceuticals. Kalorama Information remains a global leader in healthcare market intelligence, known for high-quality research, innovative analysis, and trusted insights used by top industry decision-makers and media outlets alike. View original content to download multimedia: SOURCE Kalorama Information
